REGEN-COV ™ (casirivimab and imdevimab) phase 3 RECOVERY trial meets primary outcome, improving survival in hospitalized COVID-19 patients lacking an immune response to SARS-CoV-2

Dear Investor,Please find attached a press release from our partner Regeneron:https://investor.regeneron.com/news-releases/news-release-details/regen-covtm-casirivimab-and-imdevimab-phase-3-recovery-trialDo not hesitate to contact us for any further questions.With best regards,
Source: Roche Investor Update - Category: Pharmaceuticals Source Type: news